CalciMedica (NASDAQ:CALC) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of CalciMedica (NASDAQ:CALC) in a research report report published on Thursday, Benzinga reports. HC Wainwright currently has a $20.00 price target on the stock.

Separately, Oppenheimer reaffirmed an outperform rating and set a $14.00 target price on shares of CalciMedica in a report on Monday, April 1st.

CalciMedica Trading Up 25.7 %

CALC stock opened at $3.96 on Thursday. The business’s 50-day moving average is $5.26 and its 200 day moving average is $4.62. CalciMedica has a 12-month low of $1.75 and a 12-month high of $8.38. The stock has a market cap of $42.57 million, a price-to-earnings ratio of -1.84 and a beta of 1.35.

CalciMedica (NASDAQ:CALC) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.07. As a group, equities analysts forecast that CalciMedica will post -2.05 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. BML Capital Management LLC lifted its stake in CalciMedica by 10.3% in the 1st quarter. BML Capital Management LLC now owns 160,424 shares of the company’s stock valued at $667,000 after purchasing an additional 15,000 shares during the last quarter. Meritage Portfolio Management increased its position in shares of CalciMedica by 360.0% during the fourth quarter. Meritage Portfolio Management now owns 46,000 shares of the company’s stock worth $132,000 after acquiring an additional 36,000 shares in the last quarter. Finally, Hudson Bay Capital Management LP purchased a new position in CalciMedica in the third quarter valued at about $432,000.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.